XOOMAR

Krystal Biotech, Inc. (KRYS)

Every FINRA and SEC series the site collects for Krystal Biotech, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).

Download CSV

3.2M

Short interest

settlement 2026-08-14

10.3

Days to cover

+0.1% vs prior

69.8%

Short share of volume

2026-09-11

1,767

Fails to deliver

settlement 2026-08-14

-$26.2M

Insider flow, 90 days

0 buys, 34 sells

As of 2026-09-11.

Short interest

FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSON

As of 14 August 2026, short interest in KRYS is 3,204,909 shares, down 291,739 shares over the last month. Over the last 48 readings it ranged from 2,367,240 shares (30 April 2025) to 3,699,397 shares (13 December 2024). At the reported average volume of 311K shares a day that is 10.3 days to cover, a crowded short.

Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/krys" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-08-143,204,909+0.1%310,63610.32
2026-07-313,202,260-8.4%770,9664.15
2026-07-153,496,648-0.6%307,16011.38
2026-06-303,517,595+12.1%489,2557.19
2026-06-153,138,292-0.3%288,94510.86
2026-05-293,147,863-1.1%194,30516.20
2026-05-153,183,527+2.8%397,2308.01
2026-04-303,095,771+6.3%225,02013.76
2026-04-152,912,515-7.2%259,13411.24
2026-03-313,136,891+8.6%313,29910.01
2026-03-132,887,556-2.0%240,45412.01
2026-02-272,947,930+6.9%363,4798.11
2026-02-132,757,758+1.6%248,15511.11
2026-01-302,713,674+2.1%267,77310.13
2026-01-152,656,600-0.9%354,5597.49
2025-12-312,680,099-1.5%258,74610.36
2025-12-152,720,726-5.1%343,3307.92
2025-11-282,867,935+0.1%222,78712.87
2025-11-142,865,989-0.6%385,0037.44
2025-10-312,882,886-0.2%267,12510.79
2025-10-152,889,558-15.1%299,1309.66
2025-09-303,403,495-5.6%365,6009.31
2025-09-153,603,723+4.5%352,72310.22
2025-08-293,447,590-1.0%232,27214.84

Daily short volume

FINRA Reg SHO, last 60 sessions. JSON

As of 11 September 2026, the short share of KRYS volume is 69.8%, up 5.9 points over the last five sessions. Over the last 52 readings it ranged from 56.7% (5 August 2026) to 92.0% (17 July 2026). The latest reading is 3.5 points below the 30-session average of 73.3%, on 88K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-09-1162K88K69.8%0
2026-09-1061K75K81.3%0
2026-09-0961K99K62.3%3,159
2026-09-0847K68K68.3%0
2026-09-0461K97K63.2%0
2026-09-0351K79K63.9%64
2026-09-0250K84K60.1%9
2026-09-0143K61K70.1%0
2026-08-3156K71K78.0%0
2026-08-2848K59K81.2%0
2026-08-2761K69K87.8%0
2026-08-2696K119K81.3%0
2026-08-2558K73K79.1%57
2026-08-2467K78K85.9%0
2026-08-2153K63K84.2%40
2026-08-2049K61K80.0%7
2026-08-1944K60K73.8%0
2026-08-1844K52K85.3%40
2026-08-1744K65K67.2%0
2026-08-1439K66K59.6%0
2026-08-1349K61K80.3%0
2026-08-1258K74K78.1%0
2026-08-1149K62K79.8%0
2026-08-1057K73K78.3%20
2026-08-0742K63K66.9%0
2026-08-0653K74K71.5%130
2026-08-0576K135K56.7%0
2026-08-04145K197K73.6%2,926
2026-08-03283K477K59.2%6,493
2026-07-31129K182K71.1%30

Fails to deliver

SEC, by settlement date. JSON

As of 14 August 2026, the fails-to-deliver balance in KRYS is 1,767 shares, up 1,677 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (24 November 2025) to 24,545 shares (19 February 2026). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-08-141,767$328.34$580K
2026-08-0790$322.69$29K
2026-08-04559$312.57$175K
2026-07-31168$366.85$62K
2026-07-303,245$363.28$1.2M
2026-07-296,230$364.23$2.3M
2026-07-279$335.19$3K
2026-07-16992$350.24$347K
2026-07-1586$339.43$29K
2026-07-145$363.44$2K
2026-07-0980$375.40$30K
2026-07-0819$368.60$7K
2026-07-018$371.67$3K
2026-06-3012,862$378.15$4.9M
2026-06-2997$372.25$36K
2026-06-26431$359.93$155K
2026-06-183,325$341.66$1.1M
2026-06-15967$317.97$307K
2026-06-124$321.55$1K
2026-06-11336$312.41$105K
2026-06-0911$301.76$3K
2026-06-053$307.79$923
2026-06-04387$301.82$117K
2026-06-032,107$293.21$618K
2026-04-216,493$276.50$1.8M
2026-04-1426$267.41$7K
2026-03-1011$258.65$3K
2026-03-092,097$253.69$532K
2026-02-27611$276.36$169K
2026-02-2341$261.80$11K

Insider trades

SEC Form 4, newest first, 50 of 100 shown. JSON

Insiders at KRYS reported 34 open-market sells worth $26.2M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Krishnan Suma (President, R&amp;D) on 2026-09-04.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-09-04Krishnan SumaPresident, R&amp;DSell399$366.56$146K1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell826$365.41$302K1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell1K$364.48$484K1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell565$363.34$205K1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell2K$362.65$722K1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell1K$361.61$449K1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell2K$360.47$836K1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell3K$359.39$1.2M1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell3K$358.42$1.1M1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell4K$357.57$1.4M1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell3K$356.37$1.2M1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell2K$355.57$713K1.3M
2026-09-04Krishnan SumaPresident, R&amp;DSell520$354.54$184K1.3M
2026-09-04Krishnan Krish SPresident and CEOSell405$366.56$148K1.3M
2026-09-04Krishnan Krish SPresident and CEOSell847$365.42$310K1.3M
2026-09-04Krishnan Krish SPresident and CEOSell1K$364.48$495K1.3M
2026-09-04Krishnan Krish SPresident and CEOSell573$363.34$208K1.4M
2026-09-04Krishnan Krish SPresident and CEOSell2K$362.65$729K1.4M
2026-09-04Krishnan Krish SPresident and CEOSell1K$361.61$439K1.4M
2026-09-04Krishnan Krish SPresident and CEOSell2K$360.46$817K1.4M
2026-09-04Krishnan Krish SPresident and CEOSell3K$359.39$1.2M1.4M
2026-09-04Krishnan Krish SPresident and CEOSell3K$358.42$1.1M1.4M
2026-09-04Krishnan Krish SPresident and CEOSell4K$357.57$1.4M1.4M
2026-09-04Krishnan Krish SPresident and CEOSell3K$356.37$1.2M1.4M
2026-09-04Krishnan Krish SPresident and CEOSell2K$355.57$721K1.4M
2026-09-04Krishnan Krish SPresident and CEOSell520$354.54$184K1.4M
2026-08-14ROSSI DINO An/aSell40$333.23$13K50K
2026-08-14ROSSI DINO An/aSell3K$331.43$1.0M50K
2026-08-14ROSSI DINO An/aSell5K$330.36$1.6M53K
2026-08-14ROSSI DINO An/aSell7K$329.60$2.4M58K
2026-08-14ROSSI DINO An/aSell2K$328.52$554K65K
2026-08-14ROSSI DINO An/aSell5K$327.39$1.7M67K
2026-08-14ROSSI DINO An/aSell2K$326.60$747K72K
2026-08-14ROSSI DINO An/aSell341$325.60$111K75K
2026-08-14ROSSI DINO An/aGift4K$0.00$075K
2026-06-04Krishnan SumaPresident, R&amp;DSell240$311.65$75K1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell2K$310.94$634K1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell3K$309.95$868K1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell4K$308.89$1.2M1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell13K$307.81$3.9M1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell1K$307.09$414K1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell480$305.87$147K1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell400$304.89$122K1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell247$303.17$75K1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell593$302.25$179K1.4M
2026-06-04Krishnan SumaPresident, R&amp;DSell320$300.75$96K1.4M
2026-06-04Krishnan Krish SPresident and CEOSell40$312.23$12K1.5M
2026-06-04Krishnan Krish SPresident and CEOSell964$311.36$300K1.5M
2026-06-04Krishnan Krish SPresident and CEOSell3K$310.43$823K1.5M
2026-06-04Krishnan Krish SPresident and CEOSell3K$309.49$862K1.5M

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

Planned sales (Form 144)

Newest first. JSON

2 Form 144 notices on file for KRYS worth $18.6M at the prices reported; 2 in the last 90 days worth $18.6M. Latest: SUMA KRISHNAN filed on 2026-09-04 to sell 25,000 shares ($9.3M) from 2026-09-04.

FiledSellerSharesMarket valueOf outstandingSale fromBroker
2026-09-04SUMA KRISHNANDirector, Officer, 10% Stockholder25K$9.3M0.084%2026-09-04Morgan Stanley Smith Barney LLC Executive Financial Services
2026-09-04KRISH KRISHNANDirector, Officer, 10% Stockholder25K$9.3M0.084%2026-09-04Morgan Stanley Smith Barney LLC Executive Financial Services

13F holders

Tracked managers holding KRYS at their latest 13F. JSON

7 of the 30 tracked managers held KRYS at their latest 13F, $87.8M in total at quarter-end prices. Renaissance Technologies is the largest at $22.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.

FundQuarterSharesValueOf portfolioChange in shares
Renaissance Technologies2026-06-3060K$22.2M0.03%+50K
Bridgewater Associates2026-06-3054K$20.3M0.08%+8K
Citadel Advisors2026-06-3043K$16.0M0.00%+11K
Fisher Asset Management2026-06-3028K$10.3M0.00%-108
D. E. Shaw & Co.2026-06-3028K$10.2M0.00%+17K
AQR Capital Management2026-06-3014K$5.2M0.00%-112
Two Sigma Investments2026-06-3010K$3.7M0.00%-799

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q2 2026 (quarter ended 2026-06-30) Krystal Biotech, Inc. reported revenue of $119.2M, up 24.1% from the same quarter a year earlier, and net income of $54.8M (1.79 diluted EPS). In FY 2025 it generated $200.9M of operating cash flow.

Cash
$427.7M
Equity
$1.36B
Total assets
$1.50B
Shares outstanding
29,598,836

Quarterly, last 8 quarters

QuarterPeriod endRevenueNet incomeMarginDiluted EPS
Q2 20262026-06-30$119.2M$54.8M45.9%1.79
Q1 20262026-03-31$116.4M$55.9M48.1%1.83
Q4 2025derived2025-12-31$107.1M$51.4M48.0%n/a
Q3 20252025-09-30$97.8M$79.4M81.2%2.66
Q2 20252025-06-30$96.0M$38.3M39.9%1.29
Q1 20252025-03-31$88.2M$35.7M40.5%1.20
Q4 2024derived2024-12-31$91.1M$45.5M49.9%n/a
Q3 20242024-09-30$83.8M$27.2M32.4%0.91

Fiscal years, with buybacks and dividends

Fiscal yearEndsRevenueNet incomeOperating cash flowCapexBuybacksDividends
FY 20252025-12-31$389.1M$204.8M$200.9M$12.0Mn/an/a
FY 20242024-12-31$290.5M$89.2M$123.4M$4.2Mn/an/a
FY 20232023-12-31$50.7M$10.9M-$88.8M$11.8Mn/an/a
FY 20222022-12-31$0-$140.0M-$100.6M$53.0Mn/an/a
FY 20212021-12-31$0-$69.6M-$47.9M$68.3Mn/an/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-28 from the cover page.

What this page is

Krystal Biotech, Inc. in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.

This page follows Krystal Biotech, Inc. (KRYS), SEC CIK 1711279, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.

Source and method

Short interest
FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-14.JSON and CSV
Planned sales
SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-04.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials
SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Insider trades
SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-04.JSON and CSV
Company record
EDGAR filing index for CIK 1711279Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
30 requests a minute without a key, 120 a minute with a key from a free account.

Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as biological products, (no diagnostic substances)

Datasets

Frequently Asked Questions

How much of KRYS is sold short?
3,204,909 shares were held short at the 2026-08-14 settlement, 10.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is KRYS's daily short volume?
On 2026-09-11, 61,608 of the 88,302 KRYS shares reported to FINRA were sold short, 69.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does KRYS have fails to deliver?
The SEC's latest file shows 1,767 KRYS shares failed to deliver at settlement 2026-08-14. Fails are reported per settlement date and published twice a month with a lag.
Are KRYS insiders buying or selling?
Insiders at KRYS reported 34 open-market sells worth $26.2M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Krishnan Suma (President, R&amp;D) on 2026-09-04.
Have KRYS insiders filed to sell?
2 Form 144 notices on file for KRYS worth $18.6M at the prices reported; 2 in the last 90 days worth $18.6M. Latest: SUMA KRISHNAN filed on 2026-09-04 to sell 25,000 shares ($9.3M) from 2026-09-04.
What did KRYS report last quarter?
In Q2 2026 (quarter ended 2026-06-30) Krystal Biotech, Inc. reported revenue of $119.2M, up 24.1% from the same quarter a year earlier, and net income of $54.8M (1.79 diluted EPS). In FY 2025 it generated $200.9M of operating cash flow.
Which funds hold KRYS?
7 of the 30 tracked managers held KRYS at their latest 13F, $87.8M in total at quarter-end prices. Renaissance Technologies is the largest at $22.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.